Neuroprotection in glaucoma: A model for nouroprotection in optic neuropathies

Current Opinion in Ophthalmology

Volumn 14, Issue 6, 2003, Pages 353-356

  Marcic, Tania Sibila ^a   Belyea, David Anthony ^a,b   Katz, Barrett ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b Department of Ophthalmology ^*  (United States)

Author keywords

Apoptosis; Axon; Glaucoma; Neurodegeneration; Neuroprotection; Neurorepair; Neurorescue; Neurorestoration; Optic nerve; Retinal ganglion cell

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; CALCIUM ION; CASPASE 8; GINKGO BILOBA EXTRACT; GLUTAMATE RECEPTOR ANTAGONIST; HEAT SHOCK PROTEIN; NITRIC OXIDE; TETRAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; CALCIUM HOMEOSTASIS; DRUG EFFECT; DRUG EFFICACY; GLAUCOMA; HUMAN; IMMUNOMODULATION; IMMUNOPROPHYLAXIS; NEUROMODULATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REVIEW;

ANIMALS; CASPASES; ENZYME INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; GLAUCOMA; HUMANS; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; OPTIC NERVE DISEASES; TUMOR NECROSIS FACTOR-ALPHA; VACCINES;

EID: 1542407395     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-200312000-00006     Document Type: Review

References (39)

1. Wein FB, Levin LA: Current understanding of neuroprotection in glaucoma. Curr Opin Ophthalmol 2002, 13:61-67.
2. Kass MA, Heuer DK, Higginbotham EJ, et al.: The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or preven s the onset of primary open-angle glaucoma. Arch Ophthalmol 2002, 120:701-713.
3. The AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000, 130:429-440.
4. Lichter PR, Musch DC, Gillespie BW, et al.: Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001, 108:1943-1953.
5. Heijl A, Leske MC, Bengtsson B, et al.: Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002, 120:1268-1279.
6. Levin LA: Retinal ganglion cells and neuroprotection for glaucoma. Surv Ophthalmol 2003, 48(Suppl 1):S21-S24.
7. Nicholson DW, Thornberry NA: Caspases: Killer proteases. Trends Biochem Sci 1997, 22:299-306.
8. Tezel G, Wax MB: Inhibition of caspase activity in retinal cell apoptosis induced by various stimuli in vitro. Invest Ophthalmol Vis Sci 1999, 40:2660-2667.
9. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, et al.: Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci 2002, 43:1077-1087.
10. Susin SA, Zamzami N, Kroemer G: Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1998, 1366:141-165.
11. Green DR, Reed JC: Mitochondria and apoptosis. Science 1998, 281:1309-1312.
12. Pan G, Humke EW, Dixit VM: Activation of caspases triggered by cytochrome C in vitro. FEBS Lett 1998, 426:151-154.
13. Hanninen V, Pantcheva M, Freeman E, et al.: Activation of caspase 9 in a rat model of experimental glaucoma. Curr Eye Res 2002, 25:389-395.
14. Bilsland J, Harper S: Caspases and neuroprotection. Curr Opin Investig Drugs 2002, 3:1745-1752. Good review of caspases, in general
15. Zhang J, Wu SM, Gross RL: Effects of β-adrenergic blockers on glutamate-induced calcium signals in adult mouse retinal ganglion cells. Brain Res 2003, 959:111-119.
16. Wood JPM, Schmidt K-G, Melena J, et al.: The β-adrenoceptor antagonists metipranlol and timolol are retinal neuroprotectants: comparison with betaxolol. Exp Eye Res 2003, 76:505-516.
17. Olney JW: The toxic effects of glutamate and related compounds in the retina and the brain. Retina 1982, 2:341-359.
18. Lipton SA: Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage. Surv Ophthalmol 2003, 48(Suppl 1):S38-S46. Good review of memantine, and excitoxicity
19. Bormann J: Memantine is a potent blocker of NMDA receptor channels. Eur J Pharm 1989, 166:591-592.
20. Chen H-SV, Pellegrini JW, Aggarwal SK: Open-channel block of NMDA responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 1992, 12:4427-4436.
21. Hare W, WoldeMussie E, Lai R, et al.: Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. Surv Ophthalmol 2001, 45(Suppl 3):S284-S289; discussion S295-S296.
22. Reisberg B, Doody R, Stoffler A, et al.: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003, 348:1333-1341.
23. Neufeld AH, Hernandez MR, Gonzalez M: Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol 1997, 115:497-503.
24. Liu B, Neufeld AH: Expression of NOS-2 in reactive astrocytes of the human glaucomatous optic nerve head. Glia 2000, 30:178-186.
25. Yuan L, Neufeld AH: Activated microglia in the human glaucomatous optic nerve head. J Neurosci Res 2001, 64:523-532.
26. Neufeld AH, Das S, Vora S, et al.: A prodrug of a selective inhibitor of inducible nitric oxide synthase is neuroprotective in the rat model of glaucoma. J Glaucoma 2002, 11:221-225.
27. Le DA, Lipton SA: Potential and current use of NMDA receptor antagonists in diseases of aging. Drugs Aging 2001, 18:717-724.
28. Wax MB, Tezel G: Neurobiology of glaucomatous optic neuropathy: diverse cellular events in neurodegeneration and neuroprotection. Mol Neurobiol 2002, 26:45-55.
29. Tezel G, Hernandez MR, Wax MB: Immunostaining of heat shock proteins in the retina and optic nerve head of normal and glaucomatous eyes. Arch Ophthalmol 2000, 118:511-518.
30. Ishii Y, Kwong JMK, Caprioli J: RGC protection with GGA, a heat shock protein inducer, in a rat glaucoma model. Invest Ophthalmol Vis Sci 2003, 44:1982-1992. A novel therapy and pathway for neuroprotection
31. Hirakawa T, Rokutan K, Nikawa T, et al.: GGA induces heat shock proteins in cultured guinea pig gastic mucosal cells and rat gastic mucosa. Gastroenterology 1996, 111:345-357.
32. Chao HM, Chidlow G, Melena J, et al.: An investigation into the potential mechanisms underlying the neuroprotective effect of clonidine in the retina. Brain Res 2000, 877:47-57.
33. Wheeler L, WoldeMussie E, Lai R: Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol 2003, 48(Suppl 1):S47-S51.
34. Gao H, Qiao X, Cantor LB: Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol 2002, 120:797-803.
35. Cehn H, Weber AJ: BDNF enhances retinal ganglion cell survival in cats with optic nerve damage. Invest Ophthalmol Vis Sci 2001, 42:966-974.
36. Defeudis FV: Bilobalide and neuroprotection. Pharmacol Res 2002, 46:565-568.
37. Quaranta L, Betelli S, Uva MG, et al.: Effect of Ginkgo biloba extract on pre-existing visual field damage in normal tension glaucoma. Ophthalmology 2003, 110:359-362; discussion 362-364.
38. Bakalash S, Kipnis J, Yoles E, Schwartz M: Resistance of retinal ganglion cells to an increase in intraocular pressure is immune-dependent. Invest Ophthalmol Vis Sci 2002, 43:2648-2653.
39. Schwartz M: Neurodegeneration and neuroprotection in glaucoma: development of a therapeutic neuroprotective vaccine. Invest Ophthalmol Vis Sci 2003, 44:1407-1411. Represents a novel therapy and pathway for neuroprotection